Pluvicto is owned by Aaa Usa Novartis.
Pluvicto contains Lutetium Lu-177 Vipivotide Tetraxetan.
Pluvicto has a total of 3 drug patents out of which 0 drug patents have expired.
Pluvicto was authorised for market use on 23 March, 2022.
Pluvicto is available in solution;intravenous dosage forms.
Pluvicto can be used as for treatment of adult patients with prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with androgen receptor (ar) pathway inhibition and taxane-based chemotherapy.
Drug patent challenges can be filed against Pluvicto from 2026-03-23.
The generics of Pluvicto are possible to be released after 17 October, 2034.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US11318121 | AAA USA NOVARTIS | PSMA binding ligand-linker conjugates and methods for using |
Aug, 2028
(5 years from now) | |
US10406240 | AAA USA NOVARTIS | PSMA binding ligand-linker conjugates and methods for using |
Aug, 2028
(5 years from now) | |
US10398791 | AAA USA NOVARTIS | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
Oct, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Mar 23, 2027 |
Drugs and Companies using LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN ingredient
NCE-1 date: 2026-03-23
Market Authorisation Date: 23 March, 2022
Treatment: For treatment of adult patients with prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with androgen receptor (ar) pathwa...
Dosage: SOLUTION;INTRAVENOUS
33
United States
14
Japan
14
European Union
4
China
4
Australia
3
New Zealand
3
Korea, Republic of
3
Israel
2
Hong Kong
2
Canada
2
Peru
2
South Africa
1
Spain
1
Philippines
1
Denmark
1
Poland
1
Singapore
1
Morocco
1
EA
1
Chile
1
Portugal
1
Georgia
1
Mexico
1
Saudi Arabia
1
Tunisia
1
Slovenia
1
Hungary
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic